Mutagenic impurities are a critical concern in pharmaceutical safety, governed by the ICH M7 guidelines. This deep dive explored the complex interplay of science, regulation, and manufacturing processes designed to identify, assess, and control these potentially harmful impurities.

Key points included the use of tools like QSAR (Quantitative Structure-Activity Relationship) for predicting the mutagenic potential of impurities based on molecular structure and the calculation of Acceptable Daily Intakes (ADI) to set safety thresholds tailored to a drug's intended use—whether chronic or acute.

The discussion highlighted how ICH M7 influences all stages of drug development, from preclinical studies to clinical trials and commercial manufacturing. This includes stringent stability testing to ensure drugs remain safe over time and meticulo ...